CommentEGFR mutations in circulating tumour DNA
References (10)
- et al.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Lancet Oncol
(2012) - et al.
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer
J Thorac Oncol
(2012) - et al.
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
Lung Cancer
(2011) - et al.
Cell-free nucleic acids as biomarkers in cancer patients
Nat Rev Cancer
(2011) - et al.
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing
Cancer Res
(2012)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2012 Elsevier Ltd. All rights reserved.